Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
Loading...
Embargo End Date
ICR Authors
Authors
George, DJ
Dearnaley, DP
Dearnaley, DP
Document Type
Journal Article
Date
2021-11-01
Date Accepted
2021-08-03
Abstract
Androgen deprivation therapy using gonadotropin-releasing hormone (GnRH) analogues is standard treatment for intermediate and advanced prostate cancer. GnRH agonist therapy results in an initial testosterone flare, and increased metabolic and cardiovascular risks. The GnRH antagonist relugolix is able to reduce serum testosterone levels in men with prostate cancer without inducing testosterone flare. In the HERO Phase III trial, relugolix was superior to leuprolide acetate at rapidly reducing testosterone and continuously suppressing testosterone, with faster post-treatment recovery of testosterone levels. Relugolix was associated with a 54% lower incidence of major adverse cardiovascular events than leuprolide acetate. As the first oral GnRH antagonist approved for the treatment of advanced prostate cancer, relugolix offers a new treatment option.
Citation
Future oncology (London, England), 2021, 17 (33), pp. 4431 - 4446
Source Title
Publisher
TAYLOR & FRANCIS LTD
ISSN
1479-6694
eISSN
1744-8301
1744-8301
1744-8301
Collections
Research Team
Clinical Academic Radiotherapy (Dearnaley)